###begin article-title 0
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Vpr14-88-Apobec3G Fusion Protein Is Efficiently Incorporated into Vif-Positive HIV-1 Particles and Inhibits Viral Infection
###end article-title 0
###begin p 1
Conceived and designed the experiments: XY ZA. Performed the experiments: ZY LW YZ ZA. Analyzed the data: XY ZY LW YZ ZA. Wrote the paper: XY ZA.
###end p 1
###begin p 2
###xml 89 95 <span type="species:ncbi:9606">People</span>
Current address: The Center for Disease Prevention and Control, Shijiazhuang, Hebei, The People's Republic of China
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 132 137 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 176 181 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 289 294 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 395 400 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 626 631 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G (A3G), a deoxycytidine deaminase, is a potent host antiviral factor that can restrict HIV-1 infection. During Vif-negative HIV-1 replication, A3G is incorporated into HIV-1 particles, induces mutations in reverse transcribed viral DNA and inhibits reverse transcription. However, HIV-1 Vif counteracts A3G's activities by inducing its degradation and by blocking its incorporation into HIV-1 particles. Thus, it is interesting to elucidate a mechanism that would allow A3G to escape the effects of Vif in order to rescue its potent antiviral activity and to provide a possible novel therapeutic strategy for treating HIV-1 infection.
###end p 4
###begin title 5
Methods and Findings
###end title 5
###begin p 6
###xml 313 314 313 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 711 712 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 801 802 801 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 840 841 840 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1169 1170 1169 1170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 124 129 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 324 329 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 431 436 <span type="species:ncbi:9606">human</span>
###xml 713 718 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 842 847 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In this study, we generated an R88-A3G fusion protein by fusing A3G to a virion-targeting polypeptide (R14-88) derived from HIV-1 Vpr protein and compared its antiviral effects relative to those of HA-tagged native A3G (HA-A3G). Our study showed that transient expression of the R88-A3G fusion protein in both Vif- and Vif+ HIV-1 producing cells drastically inhibited viral infection in HeLa-CD4-CCR5-cells, CD4+ C8166 T cells and human primary PBMCs. Moreover, we established CD4+ C8166 T cell lines that stably express either R88-A3G or HA-A3G by transduction with VSV-G-pseudotyped lentiviral vector that harbor expression cassettes for R88-A3G or HA-A3G, respectively, and tested their susceptibility to Vif+ HIV-1 infection. Our results clearly reveal that expression of R88-A3G in transduced CD4+ C8166 cells significantly blocked Vif+ HIV-1 infection. In an attempt to understand the mechanism underlying the antiviral activity of R88-A3G, we demonstrated that R88-A3G was efficiently incorporated into viral particles in the presence of Vif. Moreover, PCR analysis revealed that R88-A3G significantly inhibited viral cDNA synthesis during the early stage of Vif+ virus infection.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 137 138 137 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 245 250 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 287 290 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 455 460 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our results clearly indicate that R88 delivers A3G into Vif+ HIV-1 particles and inhibits infectivity and spread of the virions among CD4+ T cells. This study provides evidence for an effective strategy to modify a host protein with innate anti-HIV-1 activity and rescue its potent anti-HIV potential in the presence of Vif. Further characterization and optimization of this system may lead to the development of an effective therapeutic approach against HIV-1 infection.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 451 454 451 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Sheehy1">[1]</xref>
###xml 697 700 697 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Zhang1">[2]</xref>
###xml 701 704 701 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Mariani1">[6]</xref>
###xml 795 798 795 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Chiu1">[7]</xref>
###xml 800 803 800 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Newman1">[8]</xref>
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 37 42 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 139 144 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 445 450 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 530 535 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 588 591 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 865 868 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 894 899 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human immunodeficiency virus type 1 (HIV-1) infection of primary CD4+ T cells, macrophages and some immortalized T cell lines requires the HIV-1 encoded viral infectivity factor (Vif) protein. In the absence of Vif protein, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G; hereafter referred to as A3G), which is a cellular cytidine deaminase, was found to interfere with the replication of retroviruses, including HIV-1 [1]. A3G is efficiently incorporated into viral particles, associates with the HIV-1 reverse transcription complex (RTC), and interrupts HIV infectivity by introducing dC-to-dU mutations in the minus viral DNA strand during reverse transcription [2]-[6]. In addition to its deaminase activity, A3G directly inhibits viral reverse transcription [7], [8]. These previous observations highlight the multifaceted anti-HIV activities of A3G during HIV-1 replication.
###end p 10
###begin p 11
###xml 163 166 163 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Cen1">[9]</xref>
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Burnett1">[16]</xref>
###xml 429 432 429 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Mariani1">[6]</xref>
###xml 434 438 434 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Stopak1">[17]</xref>
###xml 439 443 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Conticello1">[23]</xref>
###xml 656 657 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 719 722 719 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Mariani1">[6]</xref>
###xml 724 728 724 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kao1">[22]</xref>
###xml 730 734 730 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kao2">[24]</xref>
###xml 735 739 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Opi1">[26]</xref>
###xml 199 204 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 658 661 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 850 855 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In activated T lymphocytes, A3G is packaged into the progeny virus through interactions with the NC domain of Gag and/or with the viral RNA during virion assembly [9]-[16]. However, during wild-type HIV-1 infection, the antiviral effects of A3G are blocked by Vif, which decreases incorporation of A3G into virions by reducing the intracellular level of A3G through accelerating ubiquitination and proteasomal degradation of A3G [6], [17]-[23]. In addition, previous studies suggest that Vif may act as an effective barrier to completely block targeting of A3G into virions, based on the observation that, even though a low level of A3G was detected in Vif+ HIV producing cells, the progeny virions remained infectious [6], [22], [24]-[26]. Thus, breaking through Vif's barrier and successfully targeting A3G into virions may promote inactivation of HIV-1 and eliminate its infectivity.
###end p 11
###begin p 12
###xml 457 461 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Bogerd1">[27]</xref>
###xml 462 466 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Xu1">[30]</xref>
###xml 489 496 489 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.,</italic>
###xml 733 737 733 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Huthoff1">[31]</xref>
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 232 237 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 410 415 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 723 728 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1376 1379 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Given that A3G exerts potent anti-HIV activity which is neutralized by the HIV-1 Vif protein, characterization of the A3G-Vif interaction is of considerable interest, as it provides a target for novel therapeutic strategies against HIV-1 infection. Recent studies have shown that a single amino-acid substitution of an aspartic acid residue to a lysine at position of 128 of A3G abrogated its interaction with HIV-1 Vif and rescued A3G's antiviral activity [27]-[30]. Furthermore, Huthoff et al., employed a molecular genetic approach to map a 3 amino-acid motif, comprised of aspartic acid-proline-aspartic acid (DPD), at amino-acid positions 128 to 130 of A3G that is a crucial region for the interaction between A3G and HIV-1 Vif [31]. In addition, a 4 amino-acid region (YYFW) adjacent to the N-terminus of the DPD motif of A3G has been identified as an important determinant for virion packaging of A3G. Such an intimate alignment of these two functional domains within A3G raises the possibility that disruption of the A3G/Vif interaction by targeting of the DPD motif with pharmaceutical agents may simultaneously interfere with recognition of the A3G packaging signal, and affect its antiviral activity. Therefore, developing novel strategies to efficiently target A3G into virions by allowing it to escape from Vif's blockage will broaden our current arsenal of anti-HIV therapies.
###end p 12
###begin p 13
###xml 66 74 66 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in trans</italic>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao1">[32]</xref>
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Lavallee1">[36]</xref>
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Wu1">[37]</xref>
###xml 409 413 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Ao1">[44]</xref>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao2">[41]</xref>
###xml 863 864 863 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 890 891 890 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1086 1087 1083 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1297 1298 1294 1295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 80 83 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 221 226 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 602 607 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 770 773 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 865 870 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1002 1007 <span type="species:ncbi:9606">human</span>
###xml 1428 1433 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vpr, a viral auxiliary protein, is efficiently incorporated in trans into HIV particles, through its interaction with the p6 domain of the Gag precursor polyprotein [32]-[36]. Its high incorporation efficiency into HIV-1 virions has enabled Vpr to deliver heterologous molecules, as Vpr fusion proteins, into the virus, thereby interfering with viral infectivity or complementing a defective virus [37]-[44]. It has also been shown that a virion-incorporation peptide R14-88 derived from Vpr can efficiently direct heterologous enzymatic proteins, such as chloramphenicol acetyltransferase, into HIV-1 particles in a p6-dependent manner [41]. In this study, we generated an R14-88-pcs-A3G (R88-A3G) fusion protein by fusing A3G to R14-88 and investigated its anti-HIV effect in the presence of Vif. Our study has shown that co-expression of R88-A3G with Vif+ HIV-1 provirus (HxBru-Vif+) drastically inhibited the infectivity of progeny virus in HeLa-CD4-CCR5-beta-Gal cells, CD4+ C8166 cells and human primary PBMCs. The same inhibitory effect was also observed in susceptible CD4+ C8166 T cell lines that stably express R88-A3G. Moreover, we found that R88-A3G was efficiently incorporated into viral particles and significantly inhibited reverse transcription during the early stage of Vif+ virus replication. These results support the hypothesis that the R88-A3G fusion protein acts as a potent antiviral agent against HIV-1 infection.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Expression of R88-A3G efficiently inhibits HIV-1 infection regardless of the presence of Vif
###end title 15
###begin p 16
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao2">[41]</xref>
###xml 298 305 298 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g001">Fig. 1A</xref>
###xml 790 791 790 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1004 1011 1004 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g001">Fig. 1B</xref>
###xml 1201 1208 1201 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g001">Fig. 1C</xref>
###xml 132 135 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 282 287 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 311 316 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 484 489 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 775 780 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 843 848 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1021 1026 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1281 1286 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We initially sought to develop a strategy to antagonize the Vif-mediated blockade of A3G incorporation, and subsequently to inhibit HIV infection. A fusion protein termed R88-A3G was generated by fusing full-length A3G to the C-terminus of a virion-incorporation domain (R14-88) of HIV-1 Vpr [41] (Fig. 1A). An HIV-1 protease cleavage site (SQNY/PIV) was inserted between R14-88 and A3G in order to release the native A3G protein in the virion through a specific cleavage mediated by HIV-1 protease. In parallel, an HA-A3G-expressorwas constructed as a control. The expression of HA-A3G and R88-A3G fusion proteins was monitored by Western blotting with the anti-A3G antibody in 293T cells transfected with either R88-A3G or HA-A3G expressor alone, or co-transfected with an HIV-1 HxBru-Vif- provirus. Our results show that, in the absence of HIV-1 expression, the R88-A3G and HA-A3G proteins were detected in transfected 293T cells with approximate molecular weights of 47 kDa and 43 kDa, respectively (Fig. 1B). In the HIV-1 expressing cells, while HA-A3G retained the same molecular weight, the majority of the R88-A3G fusion proteins had molecular weights ranging between approximately 39-40 kDa (Fig. 1C), indicating that the R88-A3G fusion protein was efficiently cleaved by HIV-1 protease.
###end p 16
###begin title 17
R88-A3G was expressed in viral producing cells and cleaved by viral protease.
###end title 17
###begin p 18
###xml 601 602 601 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 144 149 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 533 538 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A). Schematic representation of constructs of HA-A3G and R88-A3G. HA-tag or Vpr14-88 was fused in frame to the N-terminus of Apobec3G (A3G). An HIV-1 protease cleavage site (PCS) was inserted between R88 and A3G. B). HA-A3G or R88-A3G was expressed in 293T cells. 293T cells were transfected with the HA-A3G or R88-A3G expressor. After 48 hours, cell lysates were immunoprecipitated with a mixture of anti-HA and anti-Vpr antibodies followed by Western blotting with anti-A3G antibody. C). Cleavage of R88-A3G in virus produced from HIV-1 expressing cells. 293T cells were cotransfected with HxBru-Vif- provirus and the HA-A3G or R-A3G expressing plasmid. After 48 hours, produced viruses were pelleted from supernatant by ultracentrifugation through a 20% sucrose cushion, lysed, and directly loaded onto 10% SDS-PAGE followed by Western blotting with anti-A3G polyclonal antibody (upper panel) or with anti-p24 monoclonal antibody (lower panel). The positions of R88-A3G and the cleaved product of A3G are indicated at right side of gel.
###end p 18
###begin p 19
###xml 154 155 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 189 190 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 203 204 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 391 398 388 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g002">Fig. 2A</xref>
###xml 424 431 421 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g002">Fig. 2B</xref>
###xml 516 520 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kimpton1">[45]</xref>
###xml 680 681 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 726 727 723 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 745 758 742 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g002">Fig. 2A and B</xref>
###xml 905 918 902 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g002">Fig. 2A and B</xref>
###xml 43 46 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 164 169 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 319 324 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 464 469 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 571 576 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 967 970 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To determine whether R88-A3G exhibits anti-HIV activity in the presence of Vif, we co-transfected 293T cells with R88-A3G or HA-A3G plasmid and either Vif- or Vif+ HIV-1 provirus (HxBru-Vif- or HxBru-Vif+). At 48 hours post-transfection, the progeny viruses were collected and equal amounts of the viruses (adjusted by HIV-1 Gag-p24 levels) were used to infect HeLa-CD4-CCR5-beta-Gal cells (Fig. 2A) and CD4+ C8166 T cells (Fig. 2B). At 2 days post-infection, the HIV-1 infection level was monitored by a MAGI assay [45] in the infected cells or by the quantification of HIV-1 Gag-p24 antigen in the supernatants. As expected, expression of HA-A3G disrupted the infectivity of Vif- viruses, but had no inhibitory effect on Vif+ virus infection (Fig. 2A and B). Interestingly, the infectivity of the virus produced from R88-A3G expressing 293T cells was drastically inhibited regardless of Vif expression (Fig. 2A and B), indicating that R88-A3G exhibited potent anti-HIV activity by overwhelming Vif-mediated effects.
###end p 19
###begin title 20
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Expression of R88-A3G in HIV-1 producing cells inhibits virus infectivity in the presence of Vif.
###end title 20
###begin p 21
###xml 82 83 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 96 97 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 542 545 531 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gag</sup>
###xml 67 72 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 322 327 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 529 534 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 626 631 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1108 1113 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Viruses were produced from 293T cells transfected with 3 microg of HIV-1 HxBru-Vif+ or HxBru-Vif- with 4 microg of HA-A3G or R-A3G expressor. Then, equal amounts of produced viruses (as adjusted by the Gag-p24 level) were used to infect HeLa-CD4-CCR5-beta-Gal cells and CD4+ C8166 T cells. A). At 48 hours post-infection, HIV-1 infected cells were detected by MAGI assay (left panel) and counted by Elispot Reader (right panel). B). At 48 hours post-infection, virus production in of C8166 cells were monitored by measurement of HIV-1 Gag-p24gag antigen in the supernatants with p24 ELISA assay (upper panel). Cell-associated HIV-1 Gag-p24 (middle panel) and Vif (lower panel) were detected by Western blotting with anti-p24 or anti-Vif antibodies, respectively. C). pNL4.3-GFP viruses were first produced from 293T cells co-transfected by pNL4.3/GFP provirus with HA-A3G or R88-A3G. Then, equal amounts of pNL4.3-GFP viruses were used to infect C8166 T cells. At 72 hours post-infection, the percentage of infected (GFP-positive) cells was measured by FACS analysis. D). Dose-dependent effect of R88-A3G on HIV-1 infectivity. Different amounts of R88-A3G plasmid (0, 0.2, 1, 2, 4 microg) and pNL4.3-GFP proviral DNA (3 microg) were used to co-transfect 293T cells. Viruses from each transfected cell culture were collected and equal Gag-p24 amounts of viruses were used to infect C8166 T cells. 72 hours later, percentage of infected (GFP-positive) cells was measured by FACS analysis (left panel). Meanwhile, the expression of R88-A3G in the corresponding transfected 293T cells was detected by Western blotting with anti-A3G antibody (right panel).
###end p 21
###begin p 22
###xml 500 501 500 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 526 533 526 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g002">Fig. 2C</xref>
###xml 976 995 976 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g002">Fig. 2D, left panel</xref>
###xml 1068 1088 1068 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g002">Fig. 2D, right panel</xref>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To further investigate whether R88-A3G exerts an antiviral effect on other HIV-1 strains, we produced pNL4.3-GFP viruses by co-transfecting pNL4.3/GFP+/Vif+ provirus with either HA-A3G or R88-A3G expressor in 293T cells. The level of infection by progeny viruses was analyzed in CD4+ C88166 T cells by determination of the percentage of infected (GFP-positive) cells with FACS analysis. Our results clearly showed that expression of the R88-A3G fusion protein, but not HA-A3G, efficiently blocked Vif+ pNL4.3 virus infection (Fig. 2C). Furthermore, analysis of cells co-transfected with the R14-88 peptide and provirus indicated that R14-88 did not have an inhibitory effect by itself (data not shown). Moreover, a dose-dependent effect of R88-A3G was evaluated. Our results clearly showed that the antiviral effect of R88-A3G against pNL4.3 virus infection was specific to A3G and was dose-dependent, since enhancement of the inhibitory effect of R88-A3G on virus infection (Fig. 2D, left panel) was achieved by increased R88-A3G expression in virus producing cells (Fig. 2D, right panel).
###end p 22
###begin title 23
Analysis of the stability and virus-incorporation of R88-A3G in the presence of Vif
###end title 23
###begin p 24
###xml 252 255 252 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Mariani1">[6]</xref>
###xml 257 261 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Stopak1">[17]</xref>
###xml 262 266 262 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Conticello1">[23]</xref>
###xml 493 497 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Nguyen1">[46]</xref>
###xml 607 609 607 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sub>
###xml 955 962 955 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">Fig. 3A</xref>
###xml 1011 1018 1011 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">Fig. 3A</xref>
###xml 1177 1184 1177 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">Fig. 3A</xref>
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 462 467 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To understand the mechanisms whereby R88-A3G, but not HA-A3G, inhibits HIV-1 infection in the presence of Vif, we compared the intracellular expression and virion-incorporation of R88-A3G and HA-A3G. As Vif induces rapid proteasomal degradation of A3G [6], [17]-[23], we wondered whether R88-A3G fusion protein may be more resistant than HA-A3G to Vif-induced degradation. To address this question, the R88-A3G or HA-A3G plasmid was transfected alone or with an HIV-1 Vif plasmid (pcDNA-hVif) [46] into 293T cells. At 48 hours post-transfection, the stability of each protein in 293T cells was analyzed by [35S]methionine pulse-chase radiolabeling and immunoprecipitation with anti-HA or anti-Vpr antibodies, respectively. Also, Vif expression was assessed by SDS-PAGE of cell lysates, followed by Western blotting with the anti-Vif antibody. Our results showed that, in the absence of Vif, both HA-A3G and R88-A3G proteins were stable for up to 5 hours (Fig. 3A, lanes 1 to 3). In contrast, expression of Vif (Fig. 3A, lower panel, lanes 3 and 4) induced rapid degradation of both HA-A3G and R88-A3G; more than 95% of the HA-A3G and R88-A3G proteins were degraded by 5 hours (Fig. 3A, upper panel, lanes 4 to 6), suggesting that both R88-A3G and HA-A3G were equally sensitive to Vif-induced degradation.
###end p 24
###begin title 25
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 91 96 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
R88-A3G is sensitive to Vif-induced degradation, but is efficiently incorporated into Vif+ HIV-1 particles.
###end title 25
###begin p 26
###xml 224 226 224 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sub>
###xml 569 574 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1247 1253 <span type="species:ncbi:9986">rabbit</span>
A). Effect of Vif on the degradation of R88-A3G. HA-A3G or R88-A3G expressor was transfected alone or co-transfected with pcDNA-hVif expressor in 293T cells. At 48 hour post-transfection, cells were pulse radiolabeled with [35S]-methionine for 30 min, and labeled cells were collected and lysed at 0, 1.5 and 5 hours after pulse-labeling. Then, the level of HA-A3G in each lysed-cell sample was detected by anti-HA immunoprecipitation (upper panel). The level of R88-A3G in each lysed-cell sample was evaluated by anti-Vpr immunoprecipitation (middle panel). To detect HIV-1 Vif expression in different transfected cell samples, an aliquot of transfected cells from each culture was lysed and directly loaded onto 12.5% SDS-PAGE followed by Western blotting with anti-Vif antibody (lower panel). B). R88-A3G was efficiently incorporated into viral particles in the presence of Vif. 293T cells were co-transfected with HxBru-Vif+ (3ug) and HA-A3G or R88-A3G expressor (2ug). After 48 hours cells were collected and the produced virus particles were collected from supernatant by ultracentrifugation through a 20% sucrose cushion. Both cell and virus lysate samples were directly loaded onto a 12% SDS-PAGE gel and analyzed by Western blotting with rabbit anti-A3G and anti-p24, as indicated (upper panel). The ratio of R88-A3G or HA-A3G incorporation into the viral particle relative to the total amount of R88-A3G or HA-A3G was also quantified by laser densitometry (lower panel). The data presented herein are the means and standard deviations from two independent experiments.
###end p 26
###begin p 27
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 463 466 463 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Mariani1">[6]</xref>
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kao1">[22]</xref>
###xml 474 478 474 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kao2">[24]</xref>
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Opi1">[26]</xref>
###xml 600 601 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1029 1036 1029 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">Fig. 3B</xref>
###xml 1180 1189 1180 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">figure 3A</xref>
###xml 1373 1374 1373 1374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1384 1391 1384 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">Fig. 3B</xref>
###xml 1640 1649 1640 1649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">figure 3B</xref>
###xml 2046 2053 2046 2053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">Fig. 3B</xref>
###xml 289 292 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 895 901 <span type="species:ncbi:9986">rabbit</span>
Based on the above observations, we considered that the remaining non-degraded R88-A3G, but not HA-A3G, could be efficiently incorporated into virus particles in the presence of Vif. Indeed, several previous reports have indicated that, even though a low level of A3G was detected in Vif+ HIV producing cells, Vif may act as an effective barrier to prevent A3G from being incorporated virions virus and thereby completely neutralize the antiviral activity of A3G [6], [22], [24]-[26]. To address this hypothesis, we co-transfected 293T cells with the HA-A3G or R88-A3G plasmids and with the HxBru-Vif+ provirus. At 48 hours post-transfection, viral particles were collected and concentrated by ultracentrifugation through a 20% sucrose cushion. Cell- and virion-associated HA-A3G, R88-A3G and Gag-p24 were detected by 12% SDS-PAGE of cell and virus lysates followed by Western blotting with the rabbit anti-A3G and anti-p24 antibodies. Data showed that the intracellular level of R88-A3G was obviously lower than that of HA-A3G (Fig. 3B, upper panel, compare lanes 2 and 1, respectively). Since a similarly lowered level of R88-A3G was observed in the absence of Vif, as shown in figure 3A, we conclude that the expression level difference between R88-A3G and HA-A3G is Vif-independent. Intriguingly, the level of R88-A3G was significantly higher than that of HA-A3G in Vif+ virions (Fig. 3B, upper panel, compare lanes 5 and 4, respectively). To further compare the incorporation efficiency of R88-A3G and HA-A3G, levels of HA-A3G and R88-A3G in virions were quantified by densitometric scanning analysis of the autoradiogram presented in figure 3B. The levels of virion-associated R88-A3G and HA-A3G were calculated as ratios of virion-associated R88-A3G and HA-A3G protein relative to total protein levels. This ratio was adjusted relative to the level of virion-associated Gag-p24protein, which was employed as an internal control. These data illustrate that the virion-incorporation rate of R88-A3G was four-fold higher than that of HA-A3G (Fig. 3B, lower panel). These results clearly indicate that R88-A3G is efficiently incorporated into virions by evading Vif blockage.
###end p 27
###begin title 28
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 88 93 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Expression of R88-A3G does not affect virus maturation, but significantly inhibits Vif+ HIV-1 reverse transcription
###end title 28
###begin p 29
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 594 595 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 672 679 672 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g004">Fig. 4A</xref>
###xml 161 166 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 243 248 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 418 423 <span type="species:ncbi:9606">human</span>
###xml 429 432 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 473 479 <span type="species:ncbi:9986">rabbit</span>
The above results indicate that R88-A3G is efficiently incorporated into virions despite the presence of Vif. We next addressed how incorporated R88-A3G affects HIV-1 replication. Firstly, we determined whether the presence of R88-A3G affects HIV-1 maturation during virus production. The levels of virion-associated reverse transcriptase and Gag-p24 were visualized by immunoprecipitation of lysed virus-samples with human anti-HIV serum followed by Western blotting with rabbit anti-RT and anti-p24 antibodies. Similar levels of reverse transcriptase and Gag-p24 were detected in Vif+ and Vif- viruses regardless of HA-A3G or R88-A3G expression during virus production (Fig. 4A), indicating that presence of HA-A3G or R88-A3G did not affect virus maturation.
###end p 29
###begin title 30
Expression of R88-A3G does not affect virus maturation, but significantly inhibits viral cDNA synthesis.
###end title 30
###begin p 31
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 590 591 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 740 741 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 848 869 848 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 238 243 <span type="species:ncbi:9606">human</span>
###xml 249 252 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 353 359 <span type="species:ncbi:9986">rabbit</span>
###xml 809 814 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A). R88-A3G does not affect virus maturation. HxBru-Vif- and Vif+ viruses produced from 293T cells co-transfected with corresponding provirus and HA-A3G or R88-A3G expressor were pelleted, lysed and processed for immunoprecipitation with human anti-HIV serum. The immunoprecipitates were submitted to 10% SDS-PAGE and analyzed by Western blotting using rabbit anti-anti-RT antibody (upper panel) and anti-p24 antibodies (lower panel). B). R88-A3G inhibits viral cDNA synthesis at early stage of viral infection. Dividing C8166 T cells were infected with equal amounts of different HxBru-Vif+ virus stocks, which were produced from 293T cells co-transfected with the provirus and HA-A3G or R88-A3G expressor. At 12 hours post-infection, 1x106 cells were lysed and the total viral DNA was detected by PCR using HIV-1 LTR-Gag primers, as described in Materials and Methods. In parallel, the content of cellular beta-globin DNA in each sample were also examined by specific PCR analysis (lower panel).
###end p 31
###begin p 32
###xml 214 217 214 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Newman1">[8]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Bishop1">[47]</xref>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yang1">[49]</xref>
###xml 413 414 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 848 852 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Ao2">[50]</xref>
###xml 1082 1089 1082 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g004">Fig. 4B</xref>
###xml 1241 1248 1241 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g004">Fig. 4B</xref>
###xml 1538 1545 1535 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g004">Fig. 4B</xref>
###xml 1678 1679 1675 1676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 101 106 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 415 420 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1058 1061 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1680 1683 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Several studies have reported that, in the absence of Vif, encapsidated A3G is capable of inhibiting HIV-1 reverse transcription after virus entry, and that this activity is not related to A3G's deaminase activity [8], [47]-[49]. Since R88-A3G was efficiently incorporated into virions and exerted potent antiviral activity, we postulate that R88-A3G may affect reverse transcription during the early stage of Vif+ HIV-1 infection. To test this possibility, we infected C8166 cells with equal amounts HxBru-Vif+ viruses (normalized by virus-associated Gag-p24 levels) generated from 293T cells which were cotransfected with HA-A3G or R88-A3G plasmids. At 12 hours post-infection, total DNA was extracted and processed to detect total viral DNA synthesis by submitted to semi-quantitative PCR analysis using LTR-Gag primers, as described previously [50]. PCR analysis showed that similar levels of viral cDNA were present in C8166 T cells infected with wild type virus or virus produced from HA-A3G-expressing 293T cells, indicating that Vif blocked the anti-HIV activity of HA-A3G (Fig. 4B, compare lanes 3 and 4 to lanes 1 and 2). Strikingly, the reverse transcription level detected for virions containing R88-A3G was drastically reduced (Fig. 4B, lanes 5 and 6). This differential rate of viral cDNA synthesis detected among R88-A3G and wild-type/HA-A3G viruses was not due to intrinsic variation between samples since similar levels of cellular DNA (inferred from amplification of the beta-globin gene) were detected for all samples (Fig. 4B, lower panel). Together, this data indicates that virion-associated R88-A3G significantly inhibited reverse transcription during Vif+ HIV replication.
###end p 32
###begin title 33
Stable expression of R88-A3G in CD4+ C8166 cells has no effect on cell growth or CD4 expression
###end title 33
###begin p 34
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 506 527 506 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 714 718 714 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kobinger2">[51]</xref>
###xml 948 952 948 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Nguyen1">[46]</xref>
###xml 957 958 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1695 1696 1691 1692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1709 1710 1705 1706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1799 1806 1795 1802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g005">Fig. 5A</xref>
###xml 1898 1899 1894 1895 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1948 1949 1944 1945 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2028 2029 2024 2025 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2037 2038 2033 2034 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 262 265 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 632 637 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 933 938 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2148 2153 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Results from the above-mentioned experiments suggest that R88-A3G has effective antiviral activity when it is transiently over-expressed in 293T cells. We also studied whether stable low level expression of R88-A3G in CD4+ T cells exerts a similarly potent anti-HIV activity. First, we generated CD4+ C8166 T cell lines expressing either R88-A3G or HA-A3G fusion proteins by transducing C8166 T cells with a VSV-G pseudotyped lentiviral vector, which contained HA-A3G or R88-A3G transgene, as described in Materials and Methods. Briefly, lentiviral particles were produced by co-transfecting 293T cells with each lentiviral vector, HIV-1 Gag-Pol, Tat, and Rev plasmids and a VSV-G plasmid, as described previously [51]. To reduce the inhibitory effect of R88-A3G and HA-A3G on lentiviral vector transduction, we co-transfected the vector-producing with a pcDNA-hVif plasmid encoding a partially codon-optimized version of the native HIV-1 Vif gene [46]. CD4+ C8166 T cells were then transduced with the resultant lentiviral particles. Since the lentiviral vector contains a puromycin-resistance gene, the transduced cells were selected with puromycin (0.5 microg/ml) to obtain stable C8166 T cell lines expressing R88-A3G or HA-A3G. As expected, the transduction efficiency of lentiviruses containing R88-A3G was dramatically reduced (data not shown). However, through puromycin selection, we were able to obtain C8166 T cell lines stably expressing R88-A3G. The low levels of HA-A3G and R88-A3G protein present in the stably transduced cells were not detectable by anti-A3G Western blotting. However, we identified virion-incorporated HA-A3G or R88-A3G protein from highly concentrated HxBruVif- and HxBruVif+ viruses produced from these two cell lines by immunoblotting with an anti-A3G antibody (Fig. 5A). Interestingly, results revealed that while abundant amounts of HA-A3G were present in Vif- virus, there was a little HA-A3G detected in Vif+ viruses. In contrast, significant amounts of R88-A3G were detected in both Vif- and Vif+ viral particles. These results suggest that the presence of Vif could not block R88-A3G's incorporation into HIV-1 particles, which are produced from C8166 T cell line.
###end p 34
###begin title 35
The R88-A3G is stably expressed in CD4+ C8166 cells and its presence does not affect cell growth and CD4 receptor expression.
###end title 35
###begin p 36
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 486 487 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 501 502 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
C8166 T cells (10x106) were transduced with lentiviral vectors containing R88-A3G (pYEF1-R88-A3G-puro), HA-A3G (pYEF1-HA-A3G-puro) transgenes or empty vector (pYEF1-MCS-Puro), and puromycin-resistant cell population was selected by puromycin (0.5 microg/ml). Once the puromycin-resistant cell population was obtained, different analyses were performedfor their characterization. A). To detect R88-A3G and HA-A3G expression in C8166 T cells, transduced cells were infected with HxBru-Vif- and HxBru-Vif+ virus. After 72 hours of infection, the produced viruses in the supernatant were concentrated by ultracentrifugation over 20% sucrose cushions. Then, virus pellets were lysed and resolved by 10% SDS-PAGE followed by Western blotting using anti-A3G and anti-p24 antibodies. B). The CD4 receptor expression levels observed on vector- and R88-A3G-transduced C8166 T cells were analyzed by using anti-CD4 staining and a flow cytometry assay. C). The cell cycle profile of vector- and R88-A3G-transduced C8166 T cells was analyzed by measurement of the cellular DNA content by staining with 30 microg/ml of propidium iodide (PI) and flow cytometry assay. D). To assess the growth of vector- and R88-A3G-transduced C8166 T cells, a WST assay was performed to determine cell viability at different time points. Each experiment was performed in triplicate and repeated at least three times. Results are shown as the mean +/- SD of representative experiments.
###end p 36
###begin p 37
###xml 432 439 432 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g005">Fig. 5B</xref>
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 193 196 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Prior to studying the resistance of an R88-A3G expressing cell line to HIV-1 infection, we characterized the possible impact of stable expression of R88-A3G on cell growth and expression of an HIV receptor, CD4. CD4 surface receptor expression on R88-3G- and vector-transduced C8166 T cell lines were measured by anti-CD4 staining and FACS analysis. This analysis showed no difference between the two transduced C8166 T cell lines (Fig. 5B), indicating that low level R88-A3G expression had no detectable effect on CD4 surface receptor expression.
###end p 37
###begin p 38
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Levy1">[52]</xref>
###xml 76 80 76 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Re1">[55]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao3">[56]</xref>
###xml 372 393 372 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 532 545 532 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g005">Fig. 5C and D</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vpr has been shown to induce cell cycle arrest at the G2/M phase [52]-[55]. Since R14-88 was derived from Vpr, we assessed whether R88-A3G affected cell division. We analyzed the cell cycle profile and growth kinetics of R88-A3G- and vector-transduced C8166 T cell lines by performing cell cycle analysis [56] and a cell proliferation (WST-1) assay, as described in Materials and Methods. No differences in the cell cycle profile or cell growth analysis were observed between R88-3G- and vector-transduced C8166 T cell lines (Fig. 5C and D).
###end p 38
###begin title 39
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CD4+ C8166 T cells expressing R88-A3G are resistant to Vif+ HIV-1 infection
###end title 39
###begin p 40
###xml 138 139 138 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 804 805 804 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 926 946 926 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">Fig. 6A, right panel</xref>
###xml 1061 1080 1061 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">Fig. 6A, left panel</xref>
###xml 1332 1339 1332 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">Fig. 6A</xref>
###xml 1430 1437 1430 1437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">Fig. 6A</xref>
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 188 193 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 581 586 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 693 698 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 806 811 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We then assessed the resistance of R88-A3G-transduced C8166 T cells to HIV-1 infection. Vector-, HA-A3G- or R88-A3G-transduced cells (1x106 cells) were infected with equal amounts of Vif+ HIV-1 virus (pNL4.3-GFP). At 72 hours post-infection, virus-containing supernatants (passage 1) were collected. Similar volumes (1 ml) of infectious supernatant were used to infect fresh and corresponding C8166 cell lines (passage 2). At 3 days post-infection, the same volumes (1 ml) of infectious supernatant were collected and used to infect corresponding C8166 cell lines (passage 3). The HIV-1 Gag-p24 levels in supernatants collected from corresponding cultures for each passage were measured by an HIV-1 p24 ELISA. The results of this assay indicate that initial infection of R88-A3G-transduced cells with Vif+ HIV-1 (passage 1) resulted in viral production that was approximately 50% of that observed for vector-transduced cells (Fig. 6A, right panel), while the viral replication in HA-A3G-transduced cells was similar to that observed in vector-transduced cells (Fig. 6A, left panel). This data suggests that R88-A3G-transduced C8166 T cells may exert certain level of resistance to incoming virions. Strikingly, viruses collected from R88-A3G-transduced C8166 T cells were unable to mediate subsequent infection in passages 2 and 3 (Fig. 6A), suggesting that virus transmission in R88-A3G-transduced cells was efficiently blocked (Fig. 6A, passages 2 and 3).
###end p 40
###begin title 41
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The resistance of an R88-A3G-transduced CD4+ C8166 T cell line against HIV-1 infection.
###end title 41
###begin p 42
###xml 432 437 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 513 516 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 780 783 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 890 893 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A). Equal amounts of pNL4.3-GFP virus were used to infect vector-, HA-A3G-, or R88-A3G-transduced C8166 cell lines. After 48 hours of infection, virus-containing supernatants (passage 1) were collected, and the same volume of infectious supernatant was used to infect fresh and transduced C8166 cells (passage 2). The same procedure was performed again until virus-containing supernatants at assage 3 were obtained. Then, levels of HIV-1 Gag-p24 antigen in supernatants from passages 1, 2, and 3 were measured by HIV p24 ELISA assay. B). To test the effect of R88-A3G on virus infectivity, equal amounts (adjusted by Gag-p24 level) of virus from passage 1 were used to infect fresh R88-A3G-transduced C8166 cells. At different time points, the supernatants were collected and the HIV Gag-p24 level was measured to monitor virus replication. Also, at day 6 post-infection, the percentage of HIV-infected (GFP-positive) cells was evaluated by the flow cytometry assay (C).
###end p 42
###begin p 43
###xml 636 649 636 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">Fig. 6B and C</xref>
###xml 735 740 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To rule out the possibility that the reduction or loss of virus transmission in the following passages may be a result of the reduced virus production, we evaluated viral replication kinetics in R88-A3G- or vector-transduced cells by infecting cells with equal amounts of the viruses, which were normalized by Gag-p24 levels produced by the corresponding cell lines (passage 1). At every 2-day interval, Gag-p24 ELISA and the FACS analysis were performed to assess virus replication. The results of these assays revealed that progeny viruses produced from R88-A3G-transduced cells lost their replication potential over an 8-day period (Fig. 6B and C). Together, this data indicates that R88-A3G-transduced C8166 cells are resistant to HIV-1 infection and that R88-A3G may prevent virus dissemination.
###end p 43
###begin title 44
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 84 89 <span type="species:ncbi:9606">human</span>
Vif+ virus produced from R88-A3G-transduced CD4+ C8166 T cells loses infectivity in human primary mononuclear cells (PBMCs)
###end title 44
###begin p 45
###xml 163 169 163 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">Fig. 6</xref>
###xml 206 207 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 474 481 474 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g007">Fig. 7A</xref>
###xml 808 815 808 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g007">Fig. 7A</xref>
###xml 1007 1014 1007 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g007">Fig. 7B</xref>
###xml 1239 1248 1239 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g007">figure 7B</xref>
###xml 1336 1337 1336 1337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 35 40 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 223 228 <span type="species:ncbi:9606">human</span>
###xml 567 572 <span type="species:ncbi:9606">human</span>
###xml 1384 1389 <span type="species:ncbi:9606">human</span>
We assessed whether R88-A3G blocks HIV-1 infection in human PBMCs. Equal amounts of pNL4.3-GFP viruses produced from vector- or R88-A3G-transduced C8166 cells (in Fig. 6, passage 1) were used to infect 1x106 PHA-stimulated human PBMCs. At 8 hours post-infection, the PBMCs were washed and cultured in medium supplemented with 5% IL-2. At the indicated time intervals, supernatants were collected and virion-associated Gag-p24 antigen levels were measured by anti-p24 ELISA (Fig. 7A). As expected, viruses produced from vector-transduced T cells productively infected human PBMCs. However, viruses generated from R88-A3G-transduced C8166 cells were not able to initiate an efficient infection, as indicated by the very low levels of p24 antigen detected in supernatants harvested up to 9 days post-infection (Fig. 7A). Similarly, fluorescence microscopy analysis indicated relatively large numbers of infected (GFP-positive) cells among the PBMCs infected with virus produced from vector-transduced T cells (Fig. 7B, c and d). In contrast, there were very few infected (GFP-positive) cells detected in the cell pools infected with viruses containing R88-A3G. In four observed fields, only one GFP-positive cell was found, which is shown in figure 7B (e and f). Together, these results clearly indicate that the presence of R88-A3G in Vif+ virions effectively blocks virus infection of human PBMCs.
###end p 45
###begin title 46
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 86 91 <span type="species:ncbi:9606">human</span>
HIV-1 virus generated from CD4+ T cells stably expressing R88-A3G lost infectivity in human primary blood mononuclear cells (hPBMCs).
###end title 46
###begin p 47
###xml 96 104 96 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">figure 6</xref>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 158 163 <span type="species:ncbi:9606">human</span>
###xml 530 535 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Equal amounts of pNL4.3-GFP viruses produced from vector- or R88-A3G-transduced C8166 cells (in figure 6, passage 1) were used to infect 1x106 PHA-stimulated human PBMCs for 8 hours. After infection, PBMCs were washed and at different time intervals, virion-associated Gag-p24 antigen levels in the supernatant were measured by anti-p24 ELISA (A). Values were representative of data obtained from two independent experiments. At 5 days post-infection, the numbers of infected (GFP-positive) cells in mock-infected, or differently HIV-1 infected hPBMC cells, as indicated, were visualized under fluorescence microscopy (B).
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 152 155 152 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Chiu1">[7]</xref>
###xml 277 280 277 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Sheehy1">[1]</xref>
###xml 397 400 397 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Mariani1">[6]</xref>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Stopak1">[17]</xref>
###xml 407 411 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yu1">[20]</xref>
###xml 702 703 702 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 951 955 951 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao2">[41]</xref>
###xml 1338 1339 1338 1339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1425 1432 1425 1432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">Fig. 3B</xref>
###xml 1538 1539 1538 1539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 89 94 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 173 178 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 259 264 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 633 638 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 704 709 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 812 817 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 910 915 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1028 1033 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1087 1092 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1516 1521 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1550 1555 <span type="species:ncbi:9606">human</span>
###xml 1736 1741 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cellular cytidine deaminase A3G is a powerful innate antiviral factor that restricts HIV-1 infection in resting peripheral blood CD4+ T-lymphocytes [7]. However, during HIV-1 replication in activated T cells and macrophages, its action is counteracted by HIV-1 Vif protein [1]. Vif interacts with A3G and subsequently induces its degradation and prevent its incorporation into viral particles [6], [17]-[20]. Thus, determination of a mechanism whereby A3G may escape from Vif's blockage, which would rescue its potent antiviral activity, is of considerable interest, as it would provide a novel therapeutic strategy for treating HIV-1 infection. Here, we developed a strategy to target A3G into Vif+ HIV-1 particles by altering A3G's virion packaging pathway. A virus-targeting peptide (R14-88) derived from HIV-1 Vpr was fused to A3G. This peptide efficiently targets heterologous enzymatic proteins into HIV-1 particles in a p6-dependent manner [41]. We speculated that the R14-88 peptide may efficiently deliver A3G into HIV-1 particles, even in the presence of Vif. We placed an HIV-1 protease cleavage site between R14-88 and A3G to ensure that the native form of A3G is released by viral protease-mediated cleavage once the fusion protein is in the virus. Our results confirmed that R88-A3G was efficiently incorporated into Vif+ viruses and the majority of the fusion protein was converted to the native A3G form (Fig. 3B). More significantly, we demonstrated that R88-A3G expression efficiently inhibits HIV-1 infection in CD4+ cells and human PBMCs, regardless of the presence of Vif. These results provide clear evidence that the R88-A3G fusion protein is capable of overcoming Vif's blockage and significantly inhibiting HIV-1 replication.
###end p 49
###begin p 50
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Stopak1">[17]</xref>
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Marin1">[19]</xref>
###xml 158 162 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Stopak1">[17]</xref>
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yu1">[20]</xref>
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yu2">[21]</xref>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Mehle1">[57]</xref>
###xml 720 721 720 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 742 745 742 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Mariani1">[6]</xref>
###xml 747 751 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kao1">[22]</xref>
###xml 753 757 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kao2">[24]</xref>
###xml 758 762 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Opi1">[26]</xref>
###xml 943 952 943 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">figure 3A</xref>
###xml 1815 1816 1815 1816 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1836 1843 1836 1843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g003">Fig. 3B</xref>
###xml 1878 1891 1878 1891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g002">Fig. 2A and B</xref>
###xml 2145 2150 2145 2150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 2390 2394 2390 2394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Aguiar1">[58]</xref>
###xml 722 725 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1752 1755 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1817 1820 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2217 2222 <span type="species:ncbi:9606">human</span>
It is known that Vif reduces the intracellular level of A3G in virus-producing cells by inducing rapid A3G degradation [17]-[19] and inhibiting its synthesis [17]. Further studies revealed that Vif recruits cullin 5-elongin B/C E3 ubiquitin ligase which polyubiquitinates A3G and results in its proteasomal degradation [20], [21], [57]. These findings have led to the prevailing opinion that Vif inhibits A3G encapsidation by inducing its rapid degradation in virus-producing cells. In addition, several other studies suggest that Vif may act as an effective barrier to sequester A3G and prevent its incorporation into virus, even though a low level of A3G and/or degradation-resistant mutants of A3G are detected in Vif+ HIV producing cells [6], [22], [24]-[26]. Accordingly, we wonder whether the higher level of R88-A3G in the virus could be due to the lower sensitivity of R88-A3G to Vif-induced degradation. Based on the results shown in figure 3A, it is clear that R88-A3G and HA-A3G are equally susceptible to Vif-mediated degradation. Consistent with previous observations, these data suggest that the intracellular degradation of A3G may not be the sole role played by Vif in the production of infectious viruses from A3G-expressing cells. An interaction between Vif and A3G may block virion-incorporation of A3G, which may be necessary for complete neutralization of A3G. In the case of R88-A3G, the incorporation pathway of the fusion protein is different from that of A3G. This altered incorporation pathway can bypass Vif's blockage, and consequently restore A3G's antiviral activity. However, at this point, we do not know whether the efficient virion-incorporation ability of R88-A3G is the only factor that accounts for its potent anti-HIV activity, because a low level of HA-A3G was detected in Vif+ HIV virus lysates (Fig. 3B), while they were not functional (Fig. 2A and B). We speculate that, in addition to its ability to target A3G into virus particles, R14-88 may further optimize A3G's activity, possibly by altering its intraviral localization or its association with viral components. Indeed, a recent study by Aguinar et al suggested that Vpr targeted A3A (APOBEC3A), another member of the human APOBEC3 protein family, into the viral core and possibly into the ribonucleoprotein complex (RNP), but that A3A alone was only loosely associated with viral particles [58]. It is possible that, in the presence of Vif, R88-A3G is targeted to the core and associated with the RNP, which is critical for the inhibitory effect of R88-A3G. In contrast, Vif may disrupt the intraviral location of native A3G, including HA-A3G, even though a small amount of HA-A3G may be packaged in the virus. We posit that these questions merit further study.
###end p 50
###begin p 51
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 217 224 217 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g004">Fig. 4B</xref>
###xml 288 294 288 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g002">Fig. 2</xref>
###xml 471 472 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 542 543 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 658 662 658 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Goncalves1">[59]</xref>
###xml 663 667 663 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Guo2">[62]</xref>
###xml 701 706 701 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 888 892 888 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Bishop1">[47]</xref>
###xml 385 390 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The inhibition of R88-A3G on Vif+ virus infectivity was examined by measuring its effect on viral reverse transcription synthesis. Viruses produced by R88-A3G-expressing cells were defective at reverse transcription (Fig. 4B), which closely correlated with the loss of viral infectivity (Fig. 2). These observations indicate that one of main functions of R88-A3G is to directly affect HIV-1 reverse transcription, which is similar to the activity of native A3G during Vif- virus infection. Indeed, several previous studies have shown that Vif- viruses produced from A3G expressing cells produced a severely reduced level of viral DNA in newly infected cells [59]-[62]. In addition, a report by Bishop et al. revealed that the antiviral phenotype of APOBEC proteins correlates with their ability to prevent accumulation of reverse transcripts, but not with the induction of hypermutations [47]. Although R88-A3G significantly inhibits the reverse transcription step, it is worth noting that A3G's deaminase activity may contribute to the potent antiviral effect of the R88-A3G fusion protein. Further study is underway to assess the contribution of A3G deaminase activity to R88-A3G's activity, and to evaluate its contribution to the mutational burden carried by viral DNAs.
###end p 51
###begin p 52
###xml 417 418 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 511 512 511 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 578 579 578 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 803 810 803 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g005">Fig. 5A</xref>
###xml 934 935 934 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 970 976 970 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">Fig. 6</xref>
###xml 1111 1127 1111 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g005">Fig. 5B, C and D</xref>
###xml 1277 1278 1277 1278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1359 1366 1359 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">Fig. 6A</xref>
###xml 1557 1560 1557 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Chiu1">[7]</xref>
###xml 1562 1566 1562 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kreisberg1">[63]</xref>
###xml 1761 1769 1761 1769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in trans</italic>
###xml 1848 1856 1848 1856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1878 1882 1878 1882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Popov1">[64]</xref>
###xml 2272 2279 2272 2279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001995-g006">Fig. 6A</xref>
###xml 2301 2302 2301 2302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 67 72 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 936 941 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1783 1788 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our initial experiments revealed that co-expression of R88-A3G and HIV-1 in 293T cells significantly inhibited progeny virus infectivity regardless of the presence of Vif protein. Importantly, these experiments raise the concern that the effect of R88-A3G is, at least in part, due to its over-expression during viral production. Therefore, it is necessary to assess whether a lower level of R88-A3G expression in CD4+ T cells renders cells resist to viral infection. To that end, we introduced R88-A3G into CD4+ C8166 T cells by use of a lentiviral vector. These transduced CD4+ T cell lines expressed very low levels of the R88-A3G fusion protein, such that we could not detect R88-A3G protein expression in these cells. Instead, we detected R88-A3G in concentrated viruses released from these cells (Fig. 5A). Our infection experiments consistently demonstrate that a low level of R88-A3G in C8166 T cells sufficiently inhibits Vif+ HIV-1 infection and transmission (Fig. 6). It should also be noted that stable R88-A3G expression did not affect C8166 T cell growth, cell division or CD4 surface expression (Fig. 5B, C and D). Interestingly, our experiments revealed that virus production was partially reduced in R88-A3G-transduced C8166 T cells initially infected with Vif+ virus, while HA-A3G-transduced cells were fully susceptible to viral infection (Fig. 6A). This is surprising since A3G is generally observed with a high molecular mass (HMM) in activated T cells, which is not able to affect virus replication during the first round of infection [7], [63]. At this point, we do not know whether the R88-A3G fusion protein has undefined features that may affect incoming virus replication. A previous study has shown that adding recombinant Vpr could in trans complemented HIV-1 preintegration complex for its nuclear translocation in an in vitro nuclear import assay [64]. Therefore, whether the R14-88 peptide component of R88-A3G directs the fusion protein to incoming virus reverse transcription complexes and consequently affects early stages of viral replication is worthy of further investigation. Another interesting observation is that the progeny virus produced from R88-A3G-transduced C8166 T cells lost their ability to mediate subsequent infection (Fig. 6A), indicating that Vif+ virus is not transmissible in the presence of R88-A3G.
###end p 52
###begin p 53
###xml 79 82 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 118 121 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Overall, this study demonstrates a novel strategy to modify a host innate anti-HIV protein and rescue its potent anti-HIV potential, even in the presence of Vif. Further characterization and optimization of this system may lead to development of an effective therapeutic approach against this deadly viral infection.
###end p 53
###begin title 54
Materials and Methods
###end title 54
###begin title 55
Plasmid construction
###end title 55
###begin p 56
###xml 80 84 80 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Coker1">[65]</xref>
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-PetersenMahrt1">[66]</xref>
###xml 425 464 425 464 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCGGGATCCAGAGGATAGATGCCACACAATGAA-3&#8242;</named-content>
###xml 483 536 483 536 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCTCTAGATCCACCTACGATCGGATAATTCTGGCTTACTCTCCTCTG-3&#8242;</named-content>
###xml 575 580 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BamHI</italic>
###xml 587 590 587 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xba</italic>
###xml 675 679 675 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Ao3">[67]</xref>
###xml 810 813 810 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xba</italic>
###xml 823 852 823 852 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCATCTAGAAAGCCTCACTTCAG-3&#8242;</named-content>
###xml 861 864 861 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bgl</italic>
###xml 875 902 875 902 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TAAGAGCTCATGCCTGCAGCC-3&#8242;</named-content>
###xml 1329 1333 1329 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Nguyen1">[46]</xref>
###xml 1440 1441 1440 1441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1441 1445 1441 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao1">[32]</xref>
###xml 1460 1461 1460 1461 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1469 1470 1469 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1484 1488 1484 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Cohen1">[68]</xref>
###xml 1551 1552 1551 1552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1620 1624 1620 1624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao1">[32]</xref>
###xml 1683 1686 1683 1686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa</italic>
###xml 1692 1695 1692 1695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sal</italic>
###xml 1848 1851 1848 1851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa</italic>
###xml 1857 1860 1857 1860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sal</italic>
###xml 1943 1944 1943 1944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1993 1994 1993 1994 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2026 2067 2026 2067 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAGGATTAGAACATGATGACGTGTAGTAAAACACC-3&#8242;</named-content>
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 324 329 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 340 345 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1296 1301 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1409 1414 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cDNA of human APOBEC3G (A3G) was kindly provided by Dr. S.K. Petersen-Mahrt [65], [66]. To generate the CMVin-R14-88-pcs-APOBEC3G (CMVin-R88-A3G) fusion protein expressor, a cDNA was first amplified by polymerase chain reaction (PCR), which encodes for an initiation codon (ATG) followed by amino-acids from 14 to 88 of HIV-1 Vpr and a HIV-1 protease cleavage site. The primers used for the PCR are as follows: 5' oligo: 5'-GCGGGATCCAGAGGATAGATGCCACACAATGAA-3', and the 3'oligo: 5'-GCTCTAGATCCACCTACGATCGGATAATTCTGGCTTACTCTCCTCTG-3'. At the 5' and the 3' ends of cDNA, a BamHI and a XbaI site were created, respectively, and used to clone the cDNA into an SVCMVin vector [67]. The constructed plasmid was named CMVin-R14-88-pcs. Then, a full-length wild-type A3G cDNA was amplified by PCR using the 5'-A3G-XbaI primer (5'-TCATCTAGAAAGCCTCACTTCAG-3') and 3'-BglII primer (5'-TAAGAGCTCATGCCTGCAGCC-3'). The amplified A3G cDNA was cloned into CMVin-R14-88-pcs, in frame to the 3' end of R14-88-pcs, and the plasmid was named CMVin-R88-A3G. Also, a hemagglutinin (HA)-tagged A3G expression plasmid (CMVin-HA-A3G) was constructed by first fusing the A3G cDNA to 3' end of the cDNA encoding for the HA sequence (MASYPYDVPDYASL) by PCR and the amplified cDNA was cloned into the SVCMVin vector. The HIV-1 Vif expressor (pcDNA-hVif) [46] was obtained from the NIH AIDS Research and Reference Reagent Program. The HIV-1 proviral clones HxBru-Vif+[32] and pNL4.3-Nef+/GFP/Vif+ (pNL4.3-GFP) [68] were kindly provided by Dr. E. Cohen. To construct a HxBru-Vif- provirus, a two-step PCR technique, which was described previously [32], was used to amplify a cDNA encompassing a region between ApaI and SalI sites of provirus, in which amino-acids at positions 21 and 22 of Vif were changed to a stop codon. Then, the amplified PCR fragment was digested with ApaI and SalI restriction enzymes and was used to replace the corresponding region in HxBru-Vif+, and the resultant provirus was called HxBru-Vif-. The sense mutagenic primer is 5'-GAGGATTAGAACATGATGACGTGTAGTAAAACACC-3'.
###end p 56
###begin p 57
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kobinger2">[51]</xref>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SnaB</italic>
###xml 192 195 192 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kpn</italic>
###xml 315 319 315 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BamH</italic>
###xml 321 324 321 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nhe</italic>
###xml 326 329 326 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cla</italic>
###xml 724 728 724 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BamH</italic>
###xml 730 733 730 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cla</italic>
###xml 738 741 738 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nhe</italic>
###xml 743 746 743 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cla</italic>
###xml 113 116 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 404 429 <span type="species:ncbi:35269">Woodchuck hepatitis virus</span>
To generate a lentiviral vector for T cell transduction, a pEF1-pcs-puro vector was first constructed based on a HIV-based vector pHxEGFPWP [51]. Briefly, a region between SnaBI (nt 8328) and KpnI (nt 10110) in pHxEGFPWP was replaced by PCR-amplified cDNAs containing two EF1 promoters, the first one followed by a BamHI/NheI/ClaI cloning site and the second promoter linked with a puromycin gene with a Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). These cDNAs were amplified from the lentiviral vector pCDH1-MCS1-EF1-puro, which was purchased from System Biosciences (SBI). After the pYEF1-pcs-puro vector was generated, cDNAs encoding for R88-A3G or HA-A3G were cloned into this vector through BamHI/ClaI or Nhe1/ClaI sites, and the resultant plasmids were named pYEF1-R88-A3G-puro and pYEF1-HA-A3G-puro.
###end p 57
###begin title 58
Cell lines and transfection
###end title 58
###begin p 59
###xml 215 216 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 155 159 <span type="species:ncbi:9913">calf</span>
Human embryonic kidney 293T cells and HeLa-CD4/CCR5 beta-Gal cells were maintained in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% penicillin and streptomycin. The CD4+ C8166 T cell lines were maintained in RPMI-1640 medium containing 10% FCS and 1% penicillin and streptomycin PBMCs were isolated from the blood of healthy adult volunteers by sedimentation in Ficoll-Hypaque (Sigma-Aldrich Canada, Inc., Oakville, Ontario). Isolated PBMCs were stimulated with 0.1% phytohemaglutinin (PHA) and maintained in RPMI 1640 supplemented with 5% IL-2. DNA transfection of 293T cells was performed with standard calcium phosphate DNA precipitation method.
###end p 59
###begin title 60
Antibodies and chemicals
###end title 60
###begin p 61
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao1">[32]</xref>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Ao2">[50]</xref>
###xml 516 520 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao4">[69]</xref>
###xml 88 94 <span type="species:ncbi:9986">rabbit</span>
###xml 106 109 <span type="species:ncbi:9685">Cat</span>
###xml 128 131 <span type="species:ncbi:9685">Cat</span>
###xml 153 156 <span type="species:ncbi:9685">Cat</span>
###xml 320 326 <span type="species:ncbi:9986">rabbit</span>
###xml 349 354 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 364 369 <span type="species:ncbi:9606">human</span>
###xml 412 417 <span type="species:ncbi:10090">Mouse</span>
Antibodies used in immunoprecipitation or Western blotting are as follows. The purified rabbit anti-hA3G (Cat# 10201), anti-RT (Cat# 6195) and anti-Vif (Cat#2221) polyclonal antisera were obtained through the NIH AIDS Research and Reference Reagent Program. The anti-HA monoclonal antibody was purchased from Sigma. The rabbit anti-Vpr antibody and HIV-1 positive human serum 162 were described previously [32]. Mouse anti-HIVp24 and anti-CD4 monoclonal antibodies used in this study were described previously [50], [69].
###end p 61
###begin title 62
Virus production and infection
###end title 62
###begin p 63
###xml 540 544 534 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao5">[70]</xref>
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 111 116 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 395 400 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To test the effect of R88-A3G and HA-A3G on HIV-1 infection, 293T cells were co-transfected with corresponding HIV-1 proviral DNA and R88-A3G or HA-A3G plasmids. Supernatants were collected at 48 hours post-transfection and subjected to ultra-centrifugation (32,000 rpm for 1 hour at 4degreesC) to pellet the virus. Quantification of virus stocks was determined by Gag-p24 measurements using an HIV-1 p24 ELISA Kit (purchased from the AIDS Vaccine Program of the Frederick Cancer Research and Development Center) or by an RT activity assay [70]. For immunoblot analysis, viruses were pelleted by ultracentrifugation through a 20% sucrose cushion. Then, the lysed virus samples were analyzed by SDS-PAGE followed by Western blotting.
###end p 63
###begin p 64
###xml 280 284 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kimpton1">[45]</xref>
To evaluate virus infection in HeLa-CD4/CCR5-beta-Gal cells, equal amounts (adjusted by Gag-p24 levels) of virus were used to infect cells in 24-well plates. At 48 hours post-infection, the number of beta-Gal positive cells was detected by the MAGI assay, as described previously [45], and counted with an Elispot Reader (SID Autoimmune Diagnostika GmbH).
###end p 64
###begin p 65
###xml 33 38 <span type="species:ncbi:9606">human</span>
###xml 280 285 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 342 347 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 412 417 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To infect CD4+ C8166 T cells and human PBMCs, equal amounts of viruses were incubated with susceptible cells at 37degreesC for 4 hours. Then, the cells were washed and incubated with fresh medium. At different time points, viral production levels were monitored by measurement of HIV-1 Gag-p24 antigen in each infected culture supernatant by HIV-1 Gag-p24 ELISA. To evaluate the infection mediated by pNL4.3-GFP HIV-1 virus, infected cells were fixed with PBS-4% paraformaldehyde and detected by fluorescence-activated cell sorter (FACS; Becton Dickenson FACS Calibur) analysis or observed under fluorescence microscopy.
###end p 65
###begin title 66
Establishment of C8166-R88-A3G or C8166-HA-A3G cell lines
###end title 66
###begin p 67
###xml 229 233 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Kobinger2">[51]</xref>
###xml 193 196 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Production of VSV-G pseudotyped lentiviral vectors: Pseudotyped lentiviral vector stocks were produced by co-transfection of 293T cells with pYEF1-R88-A3G-puro or pYEF1-HA-A3G-puro vector, the HIV packaging plasmid pCMVDeltaR8.2 [51] and VSV-G expression plasmids. As a control, the pYEF1-mcs-puro vector was used to produce a lentiviral vector. To reduce the incorporation of R88-A3G into the vector particles, the pcDNA-hVif plasmid was co-transfected with pYEF1-R88-A3Gpuro (molar ratio 3:1). After 48 h of transfection, the vector particles (VPs) from different supernatants were concentrated by ultracentrifugation (at 32,000rpm) for 1.5 hour at 4degreesC.
###end p 67
###begin p 68
###xml 565 569 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Yao5">[70]</xref>
###xml 799 804 <span type="species:ncbi:10090">mouse</span>
###xml 896 901 <span type="species:ncbi:10090">mouse</span>
Transduction and puromycin selection: VPs (equivalent to 100 to 300 ng of Gag-p24) were incubated with C8166 T cells for overnight. After washing, transduced and non-transduced cells were incubated with fresh RPMI containing puromycin (0.5 microg/ml). The transduced C8166 T cells were under selection of puromycin for at least 10 days. As a control, non-transduced cells were likewise submitted to selection and did not survive beyond day 4 under the same concentration of puromycin. The cell cycle profile of transduced cells was analyzed as previously described [70]. The CD4 receptor expression of different transduced C8166 T cells was evaluated by anti-CD4 staining and analyzed by a fluorescence-activated cell sorter (FACS, Becton Dickenson FACS Calibur). Briefly, cells were incubated with mouse anti-CD4 (OKT4) at 4degreesC for 2 hours; the cells were then washed and stained with anti-mouse IgG-FITC in the dark for 30 min at 4degreesC. Cells were then fixed with 4% paraformaldehyde and analyzed by FACS analysis.
###end p 68
###begin p 69
###xml 277 278 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
Cell proliferation assay: The number of surviving cells was measured by the 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) assay (Roche). Briefly, pYEF1-MCS-puro and pYEF1-R88-A3G-puro transduced cells were cultured at a density of 15x103 cells/well in 96-well plates and incubated at 37degreesC. At different time points, WST (10 microl/well) was added in the culture and the cells were incubated for 4 hours at 37degreesC. After shaking thoroughly for 1 min, the absorbance was measured at 490 nm using a microplate (ELISA) reader.
###end p 69
###begin title 70
Radiolabeling, immunoprecipitation and Western blot analyses
###end title 70
###begin p 71
###xml 345 347 341 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sub>
###xml 651 656 <span type="species:ncbi:9606">human</span>
To perform pulse-chase radiolabeling experiments, 293T cells were transfected with HA-A3G or R88-A3G expressor alone or co-transfected with pcDNA-hVif expressor. After 40 hours, cells were incubated for 30 min with starve medium (DMEM without methionine, plus 10% dialyzed FBS). Then the cells were pulse-labeled for 30 min with 200 microCi of [35S]-methionine (Perkin Elmer). At the end of labeling, the radiolabeled medium was removed, and cells were washed with medium containing an excess of un-labeled methionine and incubated in complete DMEM for various times at 37degreesC. Labeled cells were then pelleted, lysed and immunoprecipitated using human anti-HA or anti-Vpr antibody. Immunoprecipitates were then resolved by 10% SDS-PAGE followed by autoradiography.
###end p 71
###begin p 72
###xml 254 260 <span type="species:ncbi:9793">donkey</span>
###xml 266 272 <span type="species:ncbi:9986">rabbit</span>
###xml 278 283 <span type="species:ncbi:9940">sheep</span>
###xml 289 294 <span type="species:ncbi:10090">mouse</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
To analyze protein expression in cells and/or in viral particles, cell lysates or lysed viral samples were directly loaded onto 10% SDS-PAGE gel and different protein levels were analyzed by Western blot with corresponding antibodies. The HRP-conjugated donkey anti-rabbit IgG, sheep anti-mouse IgG and anti-human IgG (Amersham Biosciences) were used as secondary antibodies, and protein bands were then visualized by using an enhanced chemiluminescence kit (PerkinElmer Life Science, Boston, MA).
###end p 72
###begin title 73
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 reverse-transcribed DNA detection by PCR
###end title 73
###begin p 74
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 393 394 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 674 678 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Ao2">[50]</xref>
###xml 835 839 826 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001995-Simon1">[71]</xref>
###xml 764 769 <span type="species:ncbi:9606">human</span>
C8166 T cells were infected with equal amounts of HxBru-Vif+ viruses produced from 293T cotransfected with HA-A3G or R88-A3G. Prior to infection, viruses were treated with 340U/ml DNAse (Invitrogen, Inc.) for 1 hour in 37degreesC to remove residual plasmid DNA. After 2 hours of infection, cells were washed with PBS and cultured in RPMI medium. At 12 hours post-infection, equal numbers (1x106 cells) of cells were collected, and DNA was extracted using a QIAmp DNA Blood Mini kit, following the manufacturer's instructions (QIAGEN, Valencia, Calif.). The DNA samples were processed for detecting total viral DNA synthesis by using LTR-Gag primers, as described previously [50]. To evaluate the DNA content of extracted chromosomal DNA preparations, detection of human beta-globin gene was carried-out by PCR, as described previously [71]. All final PCR products were electrophoresed through 1.2% agarose gels.
###end p 74
###begin p 75
###xml 184 187 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We thank Dr. S.K. Petersen-Mahrt and Dr. E.A. Cohen for kindly providing A3G cDNA and pNL4.3-GFP/Nef provirus, respectively. Also, we are grateful to Dr. G. Kobinger for providing the HIV-based vector pHxEGFPWP. We also thank Drs. W.C. Greene, S.L. Grice, D. Gabuzda, A.S. Bour, K. Strebel, and M. Emerman for providing anti-A3G, anti-RT, anti-Vif antibodies, pcDNA-hVif, and HeLa-CD4/CCR5-beta-Gal cells, which were obtained through the AIDS Research Reference Reagent Program, Division of AIDS, NIAID, NIH. We thank Dr. Keith Fowke and Mr. John Rutherford for their technical support.
###end p 75
###begin title 76
References
###end title 76
###begin article-title 77
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
###end article-title 77
###begin article-title 78
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
###end article-title 78
###begin article-title 79
DNA deamination mediates innate immunity to retroviral infection.
###end article-title 79
###begin article-title 80
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Hypermutation of HIV-1 DNA in the absence of the Vif protein.
###end article-title 80
###begin article-title 81
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
###end article-title 81
###begin article-title 82
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
###end article-title 82
###begin article-title 83
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
###end article-title 83
###begin article-title 84
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
###end article-title 84
###begin article-title 85
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The interaction between HIV-1 Gag and APOBEC3G.
###end article-title 85
###begin article-title 86
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
###end article-title 86
###begin article-title 87
###xml 28 49 <span type="species:ncbi:11786">murine leukemia virus</span>
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.
###end article-title 87
###begin article-title 88
###xml 29 64 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 94 99 <span type="species:ncbi:9606">human</span>
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
###end article-title 88
###begin article-title 89
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
###end article-title 89
###begin article-title 90
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 105 110 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
###end article-title 90
###begin article-title 91
###xml 28 63 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
###end article-title 91
###begin article-title 92
###xml 75 110 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker.
###end article-title 92
###begin article-title 93
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
###end article-title 93
###begin article-title 94
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
###end article-title 94
###begin article-title 95
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
###end article-title 95
###begin article-title 96
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
###end article-title 96
###begin article-title 97
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.
###end article-title 97
###begin article-title 98
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
###end article-title 98
###begin article-title 99
###xml 19 22 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
###end article-title 99
###begin article-title 100
###xml 25 60 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.
###end article-title 100
###begin article-title 101
###xml 98 133 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.
###end article-title 101
###begin article-title 102
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
###end article-title 102
###begin article-title 103
###xml 104 107 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.
###end article-title 103
###begin article-title 104
A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action.
###end article-title 104
###begin article-title 105
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
###end article-title 105
###begin article-title 106
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
###end article-title 106
###begin article-title 107
###xml 77 112 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
###end article-title 107
###begin article-title 108
###xml 22 57 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation.
###end article-title 108
###begin article-title 109
###xml 26 61 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of Gag and mutational analysis.
###end article-title 109
###begin article-title 110
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions.
###end article-title 110
###begin article-title 111
###xml 20 55 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.
###end article-title 111
###begin article-title 112
###xml 79 114 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.
###end article-title 112
###begin article-title 113
###xml 30 58 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.
###end article-title 113
###begin article-title 114
###xml 24 52 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
###end article-title 114
###begin article-title 115
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein.
###end article-title 115
###begin article-title 116
###xml 38 73 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.
###end article-title 116
###begin article-title 117
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: sequence requirement for virion incorporation and analysis of antiviral effect.
###end article-title 117
###begin article-title 118
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Complementation of integrase function in HIV-1 virions.
###end article-title 118
###begin article-title 119
###xml 84 113 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
Targeting a foreign protein into virion particles by fusion with the Vpx protein of simian immunodeficiency virus.
###end article-title 119
###begin article-title 120
###xml 50 85 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Assessment of the role of the central DNA flap in human immunodeficiency virus type 1 replication by using a single-cycle replication system.
###end article-title 120
###begin article-title 121
###xml 51 79 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated b-galactosidase gene.
###end article-title 121
###begin article-title 122
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression.
###end article-title 122
###begin article-title 123
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
###end article-title 123
###begin article-title 124
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
###end article-title 124
###begin article-title 125
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology.
###end article-title 125
###begin article-title 126
###xml 53 88 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Contribution of the C-terminal tri-lysine regions of human immunodeficiency virus type 1 integrase for efficient reverse transcription and viral DNA nuclear import.
###end article-title 126
###begin article-title 127
Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo.
###end article-title 127
###begin article-title 128
###xml 37 67 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
Induction of cell differentiation by human immunodeficiency virus 1 vpr.
###end article-title 128
###begin article-title 129
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human immunodeficiency virus type 1 Vpr gene prevents cell proliferation during chronic infection. J. Virol.
###end article-title 129
###begin article-title 130
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.
###end article-title 130
###begin article-title 131
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.
###end article-title 131
###begin article-title 132
###xml 60 95 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells.
###end article-title 132
###begin article-title 133
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
###end article-title 133
###begin article-title 134
###xml 25 28 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
VPR.A3A chimera inhibits HIV replication. J Biol Chem.
###end article-title 134
###begin article-title 135
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Role of Vif in human immunodeficiency virus type 1 reverse transcription.
###end article-title 135
###begin article-title 136
Functional domains of APOBEC3G required for antiviral activity.
###end article-title 136
###begin article-title 137
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The interaction of APOBEC3G with HIV-1 nucleocapsid inhibits tRNALys3 annealing to viral RNA. J Virol.
###end article-title 137
###begin article-title 138
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 76 111 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
###end article-title 138
###begin article-title 139
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation.
###end article-title 139
###begin article-title 140
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Viral protein R regulates nuclear import of HIV-1 pre-integration complex.
###end article-title 140
###begin article-title 141
The nuclear DNA deaminase AID functions distributively whereas cytoplasmic APOBEC3G has a processive mode of action.
###end article-title 141
###begin article-title 142
DNA deamination in immunity.
###end article-title 142
###begin article-title 143
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication.
###end article-title 143
###begin article-title 144
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 100 103 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells.
###end article-title 144
###begin article-title 145
###xml 30 65 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Degradation of CD4 induced by human immunodeficiency virus type 1 Vpu protein: a predicted alpha-helix structure in the proximal cytoplasmic region of CD4 contributes to Vpu sensitivity.
###end article-title 145
###begin article-title 146
###xml 60 95 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells.
###end article-title 146
###begin article-title 147
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.
###end article-title 147
###begin p 148
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 148
###begin p 149
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 168 171 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Funding: X-J. Yao is the recipient of the Basic Science Career Development Research Award from The Manitoba Medical Service Foundation. This work was supported by CIHR HIV preventing grant (HPR85525), CFI Leaders Opportunity Fund, University Research Grants Program (URGP) from University of Manitoba, and the grant from The Manitoba Medical Service Foundation to X-J. Yao.
###end p 149

